Abstract:e16099 Background: Neoadjuvant chemotherapy (NAC) is still the main strategy for operable local advanced gastric cancer (GC) or gastroesophageal junction cancer (EGJ). Keynote585 and Matterhorn studies had demonstrated the improvement of pathologic complete response rate (PCR), however, the overall survival benefit remains unclear. Little is known why patients’ response differently to NAC in terms of chemotherapy regiment and post neoadjuvant tumor microenvironment (TME). Methods: We retrospectively analyzed the resectable GC or EGJ patients who had been treated with neoadjuvant chemotherapy followed by surgery during 2019.11.26-2023.8.18 in the Chinese PLA general hospital. Patients with complete survival data were enrolled in the final evaluation. The association between clinical features or chemotherapy regiment and outcomes including TGR grade (NCCN criteria) and survival data were explored. Furthermore, tumor-microenvironment by means of multiplex fluorescence staining(mIHC) (CD8, CD68, CD56, PD1, PDL1, PANCK) after SOX neoadjuvant chemotherapy was analyzed. Results: 184 patients were offered neoadjuvant chemotherapy and underwent surgery. Due to follow-up lost, 141 patients with complete survival data were included in this analysis finally. Average age was 61, majority of patients were male. 85 patients received Sox and 33 received Xelox and 12 patients with docetaxel and S1(DS) and 11 patients were administered with triplets (FOLT and DOS). The median cycle of neoadjuvant treatment was 4(range from 1-7). Large proportion of patients were performed Laparoscopic. 31 patients suffered from post surgery complication. Above all, 1-year DFS and 2-year DFS, 3-year DFS rate were 72.6%, 54.8%, 49.0% respectively. 2-year OS and 3-year OS rate were 76.9%, 64.5%. PCR rate was 6.38% (n=9), which is consistent with other previous studies. 9 patients achieved TRG 0 and 26 had TRG 1. There is no statistical difference between triplets and double regiment of NEC for TRG0-1 group (45.5% vs 23.1%, p=0.099). The addition of docetaxel to oxaliplatin based therapy had not improved the TRG0-1 population compared with docetaxel-free regiment (30.4% VS 23.7%, p=0.496). YN0 is a predictor of longer survival in contrast YN+( 1-year DFS, 89.4% vs 62.8%, p=0.000).In the mIHC analyses, the density of CD8 positive and CD8+PD1- in the TGR0-1 group is higher than those cells in the TGR 2-3 group(P<0.05). TGR0-1 group had lower density of PDL1+,CD68+PDL1+ and CD68+PDL1- cells in contrast to TGR 2-3 group(P<0.05).Other multi-dimensional analyses were ongoing to be further disclosure. Conclusions: Neoadjuvant chemotherapy led to nearly 7% PCR rate for patients with local advanced GC. YN0 after NAC is a predictor of longer survival. CD8 positive and CD8+PD1- might be the determinant immune cells for better anticancer-response when exposed to chemotherapy.

Exploration of Neoadjuvant Chemotherapy for Glioma

Experimental study on the therapeutic effects of nimustine combined with cisplatin on C6 brain glioma

Preliminary Application of New Chemotherapeutic Strategy Targeting Glioma Stem Cells

The Safety and Efficacy of Immune Checkpoint Inhibitor in Combination with FOLFOX As Neoadjuvant/adjuvant Therapy in Patients with Locally Advanced Colon Cancer.

Clinical Effect of Temozolomid Combined with Concurrent Radiotherapy on High Grade Intracranial Glioma

Clinical Effects of Cisplatin Combined with Temozolomide and Radiotherapy in Treatment of Glioblastomas after Surgery

Exploration of Neoadjuvant Chemotherapy and Post-Tumor Microenvironment for Advanced Gastric Cancer (GC) or Gastroesophageal Junction Cancer (EGJ).

SYST-02 PHASE ⅡB CLINICAL TRIAL OF NEOADJUVANT CHEMOTHERAPY REVERSING GLIOMA STEM CELLS CHEMORESISTANCE IN NEWLY DIAGNOSED GBM WITH MGMT PROMOTER UNMETHYLATION

Short-term Efficacy Observation of Cisplatin Concurrent Chemotherapy Combined with Nimotuzumab McAb for Local Advanced Head and Neck Squamous Cell Cancer

[Comparison of Two Regimens of Postoperative Concurrent Chemoradiotherapy in Adult Patients with Grade III-IV Cerebral Gliomas].

Nimustine Combined with Bevacizumab for Patients with Recurrent High-Grade Gliomas:Experiences of 7 Cases

Cisplatin-based Neoadjuvant Chemotherapy in the Treatment of Patients with Advanced Bladder Cancer

Observation on the short-term clinical efficacy and safety of postoperative radiotherapy combined with temozolomide in treatment for high-grade gliomas

[A Multicenter Randomized Controlled Study of Temozolomide in 97 Patients with Malignant Brain Glioma].

Systematic Review of Adjuvant Chemotherapy for Adults with Malignant Glioma

Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial

[Individualized Chemotherapy Based on Drug Sensitivity and Resistance Assay and MGMT Protein Expression for Patients with Malignant Glioma--analysis of 42 Cases].

A clinical effect of nimustine and teniposide combination chemotherapy in patients with malignant gliomas

Comparison Of Chemotherapy Regimens For Malignant Gliomas With Positive Mgmt Protein Expression: Experience Of 51 Cases

Multicenter Randomized Study on Me-CCNU, 5-FU and ADMvsACNU, 5-FU and ADM for Treatment of Advanced Gastric Cancer

Retrospective Analysis of 56 Patients with Advanced Gastric Cancer Treated with Combination of Intravenous and Intra-Arterial Intensified Neoadjuvant Chemotherapy